• Breaking news: AMCP Dossier Format Version 5.0 is live
• Join us at AMCP Annual for Bubble Tea during the FormularyDecisions Snack & Learn 
• Don't forget to sign up for our exclusive Cencora evening reception in New Orleans
• Check out all of our other events, thought leadership sessions, and award-winning research at AMCP
• Meet with us at Asembia in April
• New and enhanced features in FormularyDecisions
• Did you miss our most recent AMCP Webinar? Watch the recording now

The AMCP Format serves as guidance for the development of dossiers as a comprehensive and standardized framework of clinical and economic evidence and information to meet the evidentiary needs of healthcare decision makers to support formulary consideration.  

In April 2024, AMCP released Version 5.0 of the AMCP Format for Formulary Submissions. Key updates to AMCP Format 5.0 include the following:  

• Special content considerations for digital therapeutics 
• More robust language to include health disparities 
• Increased emphasis on the inclusion of real-world evidence  
• Brevity encouraged to streamline dossiers
• Add-on guidance for pre-approval information exchange (PIE)  

The last AMCP Format revision (Version 4.1) was released in December 2019 and provided expanded guidance on pre-approval dossiers (for unapproved products and unapproved uses of approved products) to support PIE for early scientific dialogue between manufacturers and HCDMs.  

As with other version updates to the AMCP Format, updates to existing product dossiers are recommended when new information becomes available.  Click below for full details on the AMCP Format 5.0. 

Date/Time: Monday, April 29, 2024, from 2-2:45pm PT
Location: Wynn Convention Center

The long-awaited launch of self-administered pharmacy benefit biosimilars has marked a new beat to the ever-growing landscape of approved, launched, and pipeline products in the United States. Alongside recent launches have come innovative strategies from both industry disruptors and longstanding players to revolutionize patient access in an increasingly competitive marketplace. Coupled with ongoing regulatory/legislative considerations and the availability of real-world evidence, how are payers and providers responding to maturing and up-and-coming biosimilar products?  

Join our expert faculty as they review today’s biosimilars landscape, explore trends in uptake, and report perspectives from key stakeholders through their latest primary market research. 

• Tasmina Hydery, PharmD, MBA, BCGP, Associate Director of Digital Solutions, Cencora 
• Lakesha Farmer, PharmD, MBA, Senior Director, ION Oncology Practice Network, Cencora 
• Cate Lockhart, MS, PharmD, PhD, Executive Director, Biologics and Biosimilars Collective Intelligence Consortium 

Date/Time: Monday, April 29, 2024, from 3-3:40pm PT  
Location: Wynn Convention Center   

With one year of IRA regulations behind us, the industry is still grappling with key aspects of implementation. This session will: 

• Review IRA regulatory guidance since 2023. 
• Explore key lessons learned during the first round of drug price negotiations. 
• Delve into payer reactions and insights in response to the Medicare Part D benefit redesign.
• Assess how biopharma companies across the industry are adapting to the IRA’s implementation

Corey Ford from Cencora will equip biopharma companies with a strategic roadmap to not only respond to regulatory and payer developments, but more importantly, to proactively prepare for the impact of the IRA.

Speaker: Corey Ford, VP of Reimbursement and Policy Insights, Cencora